本帖最后由 成长的烦恼 于 2012-6-27 20:19 编辑
* F3 q! e |, z" K: l
, b) ?1 \: C$ N( G: xclinicaltrials上的三期临床链接
1 i3 ~3 i! y9 R7 E* D6 A% `
/ ]2 r; L% i/ g% H# u) b; Ehttp://clinicaltrials.gov/ct2/sh ... mp;show_locs=Y#locn
3 Y* `6 o8 x2 D
* k( ], i _" Y! J, L中国参加临床实验的城市: Y2 H! x* t2 g5 K. d6 w- u
% V/ [3 w' v! ?( l, X! o+ a- a
China, Guangdong f/ P1 t$ ?. k
' ~! D: F/ U0 y8 } }
Guangzhou, Guangdong, China, 510515 2 f7 X8 I2 h) ~% A
/ W( @! W7 s% S4 V* z
Guangzhou, Guangdong, China, 510060
, L+ V: B6 K) f$ Y) R4 |China, Jiangsu ! o" F. P% V s5 [* o
- {2 _, {$ U+ T8 ^$ Q, ]Nanjing, Jiangsu, China, 210009
@$ M: Y) j! K. n. L- a J8 ~ ) I( [3 }' l$ i! D
Nanjing, Jiangsu, China, 210002 5 N2 K6 ~) `; @, b
China, Shandong - k" C" `/ a5 e# ?' r/ `
5 q' V/ n) O- a9 L7 HQingdao, Shandong, China, 266003 7 s# D" c, @1 t$ Z0 z
China , l, }& x4 o+ c3 D: a
3 M! ?& O6 U u4 B8 [Beijing, China, 100021
% J! C9 K4 m8 @6 U' Q! K
9 _9 ] e; e6 D* o0 N( Z+ uBeijing, China, 100071
; E; m( }% }5 V2 F- b 0 A4 X8 B. @1 u, A
Changchun, China, 130021
) s4 `9 \+ M K- w, n1 N/ w( n
) A, t7 g7 V1 w6 x2 l' OChongqing, China, 400042 $ T# T6 w% f: e7 X4 Q
- O4 y" j, O$ x b" y1 M! n! SChongqing, China, 400038 6 w5 j0 }9 Y( F$ J6 }/ h0 J7 k2 t
% n6 P0 g- e( N! l y
Fuzhou, China, 350014 * J+ @& R+ }1 G. S7 x I* u- G' Q
6 V$ V$ E* {/ l. ZFuzhou, China, 350025 ) m+ E% K! b1 [! D2 d
9 S5 E) p6 S6 S9 o$ Q/ Q
Ha'erbin, China, 150040
5 T9 h" U5 u3 X% O; F& B( ~- H ; ]" Z) m. h, h: f" p
Hanghzou, China, 310009 / k4 Q' t$ \+ s8 A8 C* R
$ N, l6 y! Y- K5 l8 G8 OShanghai, China, 200001
- ]* n' ~8 D; @+ J& Q " X- N+ T! H: @* V x
Shanghai, China, 200030 V) l1 d& p o7 m) G; m' N
+ j+ X$ D! K, r7 Q3 f+ d& {* `Tianjin, China
H' a' M* }3 I. T
0 \- G: h% \) z该实验已停止招募,重新开的临床请见临床专用贴。 |